Zobrazeno 1 - 10
of 320
pro vyhledávání: ''
Autor:
Alessio Amatu, Arianna Pani, Giorgio Patelli, Oscar M. Gagliardi, Marina Loparco, Daniele Piscazzi, Andrea Cassingena, Federica Tosi, Silvia Ghezzi, Daniela Campisi, Renata Grifantini, Sergio Abrignani, Salvatore Siena, Francesco Scaglione, Andrea Sartore-Bianchi
Publikováno v:
European Journal of Cancer
Background Patients with solid tumours have high COVID-19 mortality. Limited and heterogeneous data are available regarding the immunogenicity of SARS-CoV-2 mRNA vaccines in this population. Methods and Findings This is a prospective, single-center,
Autor:
Emanuela Marcenaro, Carlotta Defferrari, Alberto Gozza, Nicoletta Sacchi, Mauro D'Amico, Matteo Clavarezza, Giacomo Siri, Nicoletta Provinciali, Oriana D’Ecclesiis, Andrea Decensi, Marco Musso, Isabella Cevasco, Nadia Menghini, Irene Maria Briata, Tania Buttiron Webber, Monica Magnani, Fortuna Paciolla, Sara Gandini, Raffaele De Palma, Martina Ugolini, Monica Boitano, Leonello Innocenti
Publikováno v:
European Journal of Cancer
Purpose Initial findings in patients with cancer suggest a lower seroconversion to SARS-COV-2 vaccination possibly related to myelo-immunosuppressive therapies. We conducted a prospective study to assess factors predicting poor seroconversion and adv
Publikováno v:
European Journal of Cancer
Background Efficacy and safety data of COVID-19 vaccines among cancer populations have been limited; however, preliminary data from recent studies have emerged regarding their immunogenicity and safety in this population. In this review, we examined
Autor:
Ivan Bièche, Catherine Guerin, Marta Jimenez, Céline Callens, Daniel Nenciu, Thomas Filleron, Nathalie Droin, Olivier Tredan, Kadija Diop, Andrea Loehr, Anthony Gonçalves, Monica Arnedos, Cecile Vicier, Fabrice Andre, Pascal Jézéquel, Marie-Paule Sablin, Anne Patsouris
Publikováno v:
European journal of cancer (Oxford, England : 1990). 159
Background Breast cancer may present genomic alterations leading to homologous recombination deficiency (HRD). PARP inhibitors have proven their efficacy in patients with HER2-negative (HER2-) metastatic breast cancer (mBC) harbouring germline (g) BR
Autor:
Jiazhi Mo, Zhihong Chi, Yan Kong, Huayan Xu, Rong Duan, Lu Si, Xieqiao Yan, Jun Guo, Xuan Wang, Caili Li, Lili Mao, Li Zhou, Jie Dai, Bin Lian, Bixia Tang, Siming Li, Xinan Sheng, Xue Bai, Chuanliang Cui
Publikováno v:
European journal of cancer (Oxford, England : 1990). 156
Purpose The combination of vascular endothelial growth factor receptor (VEGFR) inhibitor and programmed cell death-1 (PD-1) blockade provides promising therapeutic opportunities for advanced mucosal melanoma in early phase trials. The aim of this ret
Autor:
Friedegund Meier, Lydia Reinhardt, M. Schlaak, Katharina C. Kähler, Bastian Schilling, Lisa Zimmer, Valerie Glutsch, Sebastian Haferkamp, Alvaro Moreira, Tabea Wilhelm, Frank Meiss, Manuel Philip, Ralf Gutzmer, Alexander Roesch, Susanne Horn, Antje Sucker, Anne Zaremba, Selma Ugurel, Lucie Heinzerling, David Rafei-Shamsabadi, Jochen Utikal, Elisabeth Livingstone, Dirk Schadendorf, Carsten Weishaupt, Nadine Stadtler, Zeno Fiocco, Carmen Loquai, Felix Kiecker, Jessica C. Hassel, Claudia Pföhler, Kai-Martin Thoms
Publikováno v:
European journal of cancer (Oxford, England : 1990). 152
Introduction Cutaneous melanoma is notorious for the development of in-transit metastases (ITM). For unknown biological reasons, ITM remain the leading tumour manifestation without progression to distant sites in some patients. Methods In total, 191
Autor:
Julius Moratin, Subramania Iyer, Christian Freudlsperger, Linda Feeley, Ruta Gupta, Davide Mattavelli, Krishnakumar Thankappan, Carsten E. Palme, Kan Gao, Alfons J. M. Balm, Tsu-Hui Hubert Low, Cesare Piazza, Therese Ovesen, Chris Milross, Mischa de Ridder, Jonathan R. Clark, Yogesh Dokhe, Patrick Sheahan, Narayana Subramaniam, Sana D. Karam, Susanne Wiegand, Deepak Balasubramanian, Maria Pedersen, Christian Mirian, Thomas A. Gerds, Lasse Rehné Jensen
Publikováno v:
European journal of cancer (Oxford, England : 1990). 150
Background We aimed to compare the predictive performance of pN-categories in oral squamous cell carcinoma (OSCC) encompassing the most recent 8th edition (TNM8), its predecessor (TNM7), and a newly proposed algorithm (pN-N+), which classifies patien
Autor:
Dario Neri, Torsten Kessler, Walter Heindel, Wolfgang E. Berdel, Wolfgang Hartmann, Jan Philipp Hering, Eva Wardelmann, Georg Lenz, Linus Angenendt, Filippo de Braud, Teresa Hemmerle, Andrea Kerkhoff, Sant P. Chawla, Christoph Schliemann, Andrew F. Berdel
Publikováno v:
European journal of cancer (Oxford, England : 1990). 150
Background L19TNF is a recombinant fusion protein composed of a human antibody fragment and human tumour necrosis factor. L19TNF targets the EDB domain of oncofetal fibronectin highly expressed in tumour vasculature and induces tumour remission in mo
Autor:
Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch, Judith Balmaña, Suzette Delaloge, Intidhar Labidi-Galy, James Bennett, Susan McCutcheon, Graham Walker, Joyce O'Shaughnessy, Constanta Timcheva, Antoaneta Tomova, Andrea Eisen, Karen Gelmon, Julie Lemieux, Fernando Bazan, Hugues Bourgeois, Camille Chakiba, Mohamad Chehimi, Florence Dalenc, Thibault De La Motte Rouge, Jean-Sébastien Frenel, Anthony Gonçalves, Anne Claire Hardy-Bessard, Regine Lamy, Christelle Levy, Alain Lortholary, Audrey Mailliez, Jacques Medioni, Anne Patsouris, Dominique Spaeth, Luis Teixeira, Isabelle Tennevet, Cristian Villanueva, Benoit You, Johannes Ettl, Bernd Gerber, Oliver Hoffmann, Tjoung-Won Park-Simon, Mattea Reinisch, Joke Tio, Pauline Wimberger, Katalin Boer, Alberto Ballestrero, Giampaolo Bianchini, Laura Biganzoli, Roberto Bordonaro, Francesco Cognetti, Michelino De Laurentiis, Sabino De Placido, Valentina Guarneri, Filippo Montemurro, Giuseppe Naso, Armando Santoro, Claudio Zamagni, Seung-Jin Kim, Seigo Nakamura, Yee Soo Chae, Eun Kyung Cho, Kim Jee Hyun, Seock-Ah Im, Keun Seok Lee, Yeon Hee Park, Joo Hyuk Sohn, Tomasz Byrski, Tomasz Huzarski, Bozena Kukielka-Budny, Zbigniew Nowecki, Renata Szoszkiewicz, Rafal Tarnawski, Viktoria Dvornichenko, Fedor Moiseenko, Guzel Mukhametshina, Elena Poddubskaya, Ekaterina Popova, Anna Tarasova, Anna Vats, Bárbara Adamo, Raquel Andrés Conejero, Antonio Antón Torres, Judith Balmaña Gelpi, Nieves Díaz Fernández, Alejandro Falcón González, Juan Garcia, Isabel Lorenzo-Lorenzo, Fernando Moreno Antón, Marta Santisteban, Agostina Stradella, Chiun-Sheng Huang, Sercan Aksoy, Cagatay Arslan, Mehmet Artac, Adnan Aydiner, Ozgur Ozyilkan, Emel Sezer, Anne Armstrong, Sophie Barrett, Annabel Borley, Zoe Kemp, Caroline Michie, Mukesh Mukesh, Timothy Perren, Angela Swampillai, Tammy Young
Publikováno v:
European journal of cancer (Oxford, England : 1990). 152
Background In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-nega
Autor:
E. Novel-Catin, Stéphane Dalle, Denis Fouque, C. Teuma, M. Espi, Pierre-Jean Souquet, Denis Maillet, Laetitia Koppe
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2021, 147, pp.29-39. ⟨10.1016/j.ejca.2021.01.005⟩
European Journal of Cancer, Elsevier, 2021, 147, pp.29-39. ⟨10.1016/j.ejca.2021.01.005⟩
European Journal of Cancer, 2021, 147, pp.29-39. ⟨10.1016/j.ejca.2021.01.005⟩
European Journal of Cancer, Elsevier, 2021, 147, pp.29-39. ⟨10.1016/j.ejca.2021.01.005⟩
Acute Kidney Injury (AKI), induced by Checkpoint Inhibitors therapies (CPI-induced AKI), is an uncommon but severe Immune-Related Adverse Event (IRAE). The aim was to describe the epidemiology, risks factors, clinical, and laboratory characteristics